DRC Launches R21 Malaria Vaccine to Combat Child Mortality
The introduction of the R21 malaria vaccine in the Democratic Republic of the Congo (DRC) represents a significant advancement in the fight against malaria. It is especially important for protecting vulnerable groups, such as young children. This initiative is critical for addressing the pressing public health challenges associated with malaria in the region.
Introduction of the R21 Malaria Vaccine
The R21 malaria vaccine’s inclusion in the national immunisation program marks a key step in combating malaria, especially in young children.
Vaccine Distribution and Target
The country has received 693,500 doses of the R21 malaria vaccine. The first phase of the rollout targeting 173,375 children in 31 health zones of the Kongo Central province.
Partners and Support
The introduction is supported by various partners, including WHO, UNICEF, Gavi, the Vaccine Alliance, the Clinton Health Access Initiative, PATH, Breakthrough Action, and SANRU, a national NGO. These partners are providing essential technical guidance, training health workers, and implementing effective public awareness and communication strategies.
Impact of Malaria in DRC
Malaria is a significant public health issue in the DRC, causing over 24,000 deaths and infecting more than 27 million people, primarily children under five years old. This alarming statistic comes from the 2022 report by the Ministry of Public Health, Hygiene and Social Welfare.
National Strategic Plan
The DRC is intensifying malaria control efforts through a 2024-2028 National Strategic Plan. This plan includes mass distribution of next-generation insecticide-treated nets, expanded preventive treatments for pregnant women and infants, seasonal malaria chemoprevention, and enhanced vector control.
Integration with Existing Measures
The introduction of the R21 malaria vaccine is part of a comprehensive strategy that combines various WHO-recommended interventions tailored to the local context. This includes indoor residual spraying, effective larval source management, rapid diagnostics, and artemisinin-based therapies.
Community and Leadership Involvement
Administrative, political, religious, and community leaders in Kongo Central province have been sensitized and actively involved in the preparations. Their collaboration ensures effective ownership and implementation of the vaccine rollout, a critical component in the campaign against malaria.
Broader Context
With this initiative, the DRC becomes the 15th country in Africa to offer malaria vaccination. Therefore, contributing to the continental campaign to combat malaria, aligning with the Accelerating Malaria Vaccine Introduction and Rollout in Africa (AMVIRA) initiative. AMVIRA aims to enhance technical support and coordination for malaria vaccine rollout in African nations
Overall, the R21 malaria vaccine is a vital element in the DRC’s strategy to mitigate malaria’s devastating impact. Coupled with robust vector control measures and community engagement, represents a multifaceted approach in the urgent fight against malaria.
